Elevance Health (ELV) Earnings Date & Reports

Key Takeaways

• Elevance Health is scheduled to report third-quarter 2026 results on October 21, 2026, before the market opens.
• Wall Street consensus calls for adjusted earnings per share (EPS, a measure of profit per outstanding share) of about $4.66, down from $6.03 a year earlier, on revenue near $49 billion.
• Management raised its full-year 2026 adjusted EPS guidance to at least $27.00 following a second-quarter beat driven by stronger Medicare Advantage results.
• Medicaid remains the biggest watch item, with a projected full-year operating margin near negative 1.75% and plans to exit additional markets.
• Carelon revenue growth and Medicare Advantage margin recovery are expected to anchor the forward outlook.

Earnings Context and Why It Matters

Elevance Health (NYSE: ELV), the Indianapolis-based managed care and pharmacy services company formerly known as Anthem, is navigating a transitional year. The company is deliberately shrinking less profitable government business while investing in higher-growth services under its Carelon umbrella. In the second quarter of 2026, adjusted EPS of $7.45 beat estimates by roughly 20%, yet shares fell on lingering Medicaid concerns. Because government-funded programs represent a large share of Elevance's membership, investors closely watch medical cost trends, the benefit expense ratio, and membership retention. The October report will test whether the company's repositioning strategy is translating into sustainable margin stability heading into 2027.

Earnings Expectations

For the third quarter of 2026, analysts expect Elevance Health to report adjusted EPS of approximately $4.66, according to consensus estimates, compared with $6.03 in the prior-year period. Revenue is projected to come in near $49 billion. For the full fiscal year 2026, Wall Street models adjusted EPS of about $27.19, slightly above management's raised guidance of at least $27.00.

Several metrics will draw investor attention beyond the headline numbers. The benefit expense ratio (the share of premiums spent on medical care) rose to 89.7% in the second quarter, reflecting elevated medical cost trend in government businesses. Days in Claims Payable, a liquidity measure of how quickly claims are settled, stood at 45.4 days. Membership trends also matter: total medical membership declined to about 44.9 million in Q2, driven by Medicaid and Medicare Advantage attrition. Carelon, which includes CarelonRx pharmacy and Carelon Services, grew revenue 6% year over year to $19.2 billion and will be a key gauge of diversification.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Elevance Health alongside peers in the healthcare sector, the AI Screener offers a streamlined way to surface relevant opportunities as earnings season unfolds.

Market Reaction and Investor Sentiment

Sentiment heading into the report is cautious but constructive. Elevance has beaten bottom-line estimates in each of the past four quarters, and analysts assign the stock a consensus "Moderate Buy" rating with an average price target near $450, implying potential upside from current levels around $410. Still, the stock's reaction to the Q2 beat, when shares fell more than 10%, shows that the market is more focused on the quality and durability of margins than on headline EPS surprises. Key risk factors heading into the release include any unexpected step-up in Medicaid medical costs, membership attrition in government lines, and execution around planned market exits. Investors will also watch whether the company reaffirms or updates its full-year guidance.

Forward Outlook and Key Factors to Monitor

Management has signaled that 2026 is expected to mark the trough for Medicaid margins, with improvement anticipated as rate updates take effect and care management actions mature. Investors will be listening for confirmation that second-half Medicaid performance is improving relative to the first half, supported by July 1 rate activity.

Medicare Advantage is another area of focus. Elevance reported stronger-than-expected results in the second quarter and remains on track for at least a 2% operating margin in that business this year. Commentary on 2027 bids and medical cost trend assumptions will offer insight into whether that recovery can extend.

Finally, Carelon's growth trajectory matters. The segment's expansion into risk-based services and specialty pharmacy is central to Elevance's plan to diversify beyond core insurance. Management has expressed confidence in returning to at least 12% adjusted EPS growth in 2027 off a higher earnings baseline, and any update to that framework will be closely scrutinized. For now, the focus remains on cost discipline, membership stability, and whether diversified growth can cushion pressure in government-funded health programs.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations